Mersana Therapeutics buy Guggenheim
Start price
16.05.25
/
50%
€0.31
Target price
16.05.26
€4.46
Performance (%)
-14.13%
End price
17.05.26
-
Summary
This prediction is currently being closed. The prediction for Mersana Therapeutics disappoints with a performance of -14.13%. Guggenheim has a follow-up prediction for Mersana Therapeutics where he still thinks Mersana Therapeutics is a Buy. Guggenheim has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Mersana Therapeutics | - | - | - |
| iShares Core DAX® | 1.717% | 3.368% | 5.887% |
| iShares Nasdaq 100 | -4.565% | -4.238% | 21.386% |
| iShares Nikkei 225® | -7.120% | -11.869% | 42.357% |
| iShares S&P 500 | -0.894% | 1.687% | 19.495% |
Comments by Guggenheim for this prediction
In the thread Mersana Therapeutics diskutieren
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $5.00 price target on the stock.
Ratings data for MRSN provided by MarketBeat
In the thread Trading Mersana Therapeutics
Die von Guggenheim gewählte maximale Laufzeit wurde überschritten